AR033622A1 - Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo - Google Patents
Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipoInfo
- Publication number
- AR033622A1 AR033622A1 ARP020101139A ARP020101139A AR033622A1 AR 033622 A1 AR033622 A1 AR 033622A1 AR P020101139 A ARP020101139 A AR P020101139A AR P020101139 A ARP020101139 A AR P020101139A AR 033622 A1 AR033622 A1 AR 033622A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- group
- ch2c
- independently selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- -1 aryl oxime piperazine compound Chemical class 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto aril oxima-piperazinas que incluye enantiomeros, estereoisoméricos, rotámeros, tautomeros, racematos y prodrogas de dicho compuesto, y sales o solvatos farmacéuticamente aceptables de dicho compuesto o de dicha prodroga, teniendo dicho compuesto la estructura general de formula (1), en la cual: X está seleccionado del grupo que consiste en H, F, Cl, Br, I, -CF3, -CF3O, -CN, CH3SO2-, y CF3SO2-; R1 es H, alquilo de cadena recta o alquilo de cadena ramificada, fluoro-alquilo C1-6, alquileno C1-6 portador de un cicloalquilo C3-7 (por ejemplo, ciclopropilmetilo), -CH2CH2OH, -CH2CH2-O-(C1-6)alquilo, -CH2C(O)-O-(C1-6)alquilo, -CH2C(O)NH2, -CH2C(O)-NH(C1-6)alquilo, o -CH2C(O)-N((C1-6)alquilo)2; R2 es H, un alquilo C1-6 de cadena recta o un alquilo de cadena ramificada, o alquenilo C2-6; R3 es alquilo C1-6 de cadena recta o alquilo ramificado; fenilo sustituido con R4, R5, R6; heteroarilo de 6 miembros sustituido con R4, R5, R6; N-oxido de heteroarilo de 6 miembros sustituido con R4, R5, R6; heteroarilo de 5 miembros sustituido con R7, R8; naftilo; fluorenilo; difenilmetilo; un resto de formula (2); o un resto de formula (3); donde R4 y R5 pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en alquilo C1-6, halogeno, -NR12R13, -OH, -CF3, -OCH3, -O-acilo, -OCF3 y -Si(CH3)3; R6 es R4, hidrogeno, fenilo, -NO2, -CN, -CH2F, -CHF2, -CHO, -CH=NOR12, piridilo, N-oxido de piridilo, pirimidinilo, pirazinilo, -N(R12)CONR13R14, -NHCONH(cloro-(C1-6)alquilo), -NHCONH((C3-10)cicloalquilo(C1-6)alquilo), NHCO(C1-6)alquilo, -NHCOCF3, -NHSO2N((C1-6)alquilo)2, -NHSO2(C1-6)alquilo, -N(SO2CF3), -NHCO2(C1-6)alquilo, cicloalquilo C3-10, -SR15, -SOR15, SO2R15, -SO2NH(C1-6)alquilo, -OSO2(C1-6)alquilo, -OSO2CF3, hidroxi(C1-6)alquilo, -CONR12R13, -CON(CH2CH2-O-CH3)2, -OCONH(C1-6)alquilo, -CO2R2, -Si(CH3)3 o -B(OC(CH3)2); R7 es alquilo C1-6, -NH2 o R9-fenilo; R9 es 1 a 3 sustituyentes que pueden ser iguales o diferentes y que están independientemente seleccionados del grupo que consiste en hidrogeno, alquilo C1-6, -CF3, -CO2R12, -CN, alcoxi C1-6 y halogeno; R10 y R11 pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en hidrogeno y alquilo C1-6, o R10 y R11 conjuntamente son un grupo alquileno C2-5 y con el átomo de carbono al cual están unidos forman un anillo espiro de 3 a 6 átomos de carbono; R12, R13 y R14 pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste de H y alquilo C1-6; y R15 es alquilo C1-6 o fenilo; las composiciones farmacéuticas que contienen uno o más de los compuestos, uso de dichos compuestos para la manufactura de medicamentos para el tratamiento, prevencion y mejora de una o más enfermedades asociadas con el receptor CCR5 y un equipo que comprende envases separados en un solo paquete, composiciones farmacéuticas para usarlas en combinacion para tratar el Virus de Inmunodeficiencia Humana que comprende en un envase una composicion farmacéutica que comprende una cantidad eficaz de un antagonista CCR5 de la reivindicacion 1, en un portador farmacéuticamente aceptable, y en envases separados, una o más composiciones farmacéuticas que comprenden una cantidad eficaz de un agente antiviral u otro agente util en el tratamiento del Virus de Inmunodeficiencia Humana en un portador farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995001P | 2001-03-29 | 2001-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033622A1 true AR033622A1 (es) | 2003-12-26 |
Family
ID=23071025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101139A AR033622A1 (es) | 2001-03-29 | 2002-03-27 | Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6689783B2 (es) |
| EP (1) | EP1373206B1 (es) |
| JP (1) | JP4303969B2 (es) |
| KR (1) | KR20030083015A (es) |
| CN (1) | CN1253435C (es) |
| AR (1) | AR033622A1 (es) |
| AT (1) | ATE418542T1 (es) |
| AU (1) | AU2002303168B2 (es) |
| CA (1) | CA2442210C (es) |
| DE (1) | DE60230491D1 (es) |
| ES (1) | ES2318009T3 (es) |
| HU (1) | HUP0400389A3 (es) |
| IL (1) | IL157713A0 (es) |
| MX (1) | MXPA03008801A (es) |
| MY (1) | MY134019A (es) |
| NZ (1) | NZ528011A (es) |
| WO (1) | WO2002079157A1 (es) |
| ZA (1) | ZA200307171B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825121B2 (en) | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| US7705153B2 (en) * | 2004-02-05 | 2010-04-27 | Schering Corporation | Bipiperdine derivatives useful as CCR3 antagonists |
| GEP20094680B (en) | 2004-04-13 | 2009-05-10 | Incyte Corp | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| US20070215685A1 (en) * | 2005-02-03 | 2007-09-20 | Yottamark, Inc. | System and Method of Product Identification Using a URL |
| MX2007010258A (es) * | 2005-02-23 | 2007-09-11 | Schering Corp | Derivados de piperidinil piperazina utiles como inhibidores de receptores de quimiocina. |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| KR100830003B1 (ko) * | 2006-10-31 | 2008-05-15 | 씨제이제일제당 (주) | 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법 |
| US20080173808A1 (en) * | 2007-01-18 | 2008-07-24 | Schering Corporation | Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms) |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| IL295400A (en) | 2020-02-19 | 2022-10-01 | Ichilov Tech Ltd | Improved treatment for depression |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4949314A (en) | 1966-08-16 | 1990-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Method and means for increasing echo-ranging-search rate |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| GB8327880D0 (en) | 1983-10-18 | 1983-11-16 | Ajinomoto Kk | Saccharomyces cerevisiae |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| IL76360A0 (en) | 1984-09-26 | 1986-01-31 | Takeda Chemical Industries Ltd | Mutual separation of proteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| NZ230045A (en) | 1988-08-05 | 1990-11-27 | Janssen Pharmaceutica Nv | 3-piperazinylbenzazole derivatives and pharmaceutical compositions |
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| CA2212370A1 (en) | 1995-02-16 | 1996-08-22 | Moses Judah Folkman | Inhibition of angiogenesis using interleukin-12 |
| ES2244437T3 (es) * | 1999-05-04 | 2005-12-16 | Schering Corporation | Derivados de piperazina utiles como antagonistas de ccr5. |
-
2002
- 2002-03-27 AT AT02731174T patent/ATE418542T1/de not_active IP Right Cessation
- 2002-03-27 DE DE60230491T patent/DE60230491D1/de not_active Expired - Lifetime
- 2002-03-27 HU HU0400389A patent/HUP0400389A3/hu unknown
- 2002-03-27 EP EP02731174A patent/EP1373206B1/en not_active Expired - Lifetime
- 2002-03-27 AU AU2002303168A patent/AU2002303168B2/en not_active Expired - Fee Related
- 2002-03-27 MX MXPA03008801A patent/MXPA03008801A/es active IP Right Grant
- 2002-03-27 CN CNB028076567A patent/CN1253435C/zh not_active Expired - Fee Related
- 2002-03-27 WO PCT/US2002/009490 patent/WO2002079157A1/en not_active Ceased
- 2002-03-27 US US10/107,992 patent/US6689783B2/en not_active Expired - Fee Related
- 2002-03-27 CA CA002442210A patent/CA2442210C/en not_active Expired - Fee Related
- 2002-03-27 NZ NZ528011A patent/NZ528011A/en unknown
- 2002-03-27 IL IL15771302A patent/IL157713A0/xx unknown
- 2002-03-27 ES ES02731174T patent/ES2318009T3/es not_active Expired - Lifetime
- 2002-03-27 JP JP2002577784A patent/JP4303969B2/ja not_active Expired - Fee Related
- 2002-03-27 AR ARP020101139A patent/AR033622A1/es unknown
- 2002-03-27 KR KR10-2003-7012566A patent/KR20030083015A/ko not_active Withdrawn
- 2002-03-28 MY MYPI20021141A patent/MY134019A/en unknown
-
2003
- 2003-09-12 ZA ZA200307171A patent/ZA200307171B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004524360A (ja) | 2004-08-12 |
| ZA200307171B (en) | 2004-12-13 |
| AU2002303168B2 (en) | 2005-10-06 |
| HUP0400389A3 (en) | 2008-03-28 |
| US20030087912A1 (en) | 2003-05-08 |
| WO2002079157A1 (en) | 2002-10-10 |
| NZ528011A (en) | 2004-08-27 |
| HUP0400389A2 (hu) | 2004-08-30 |
| EP1373206B1 (en) | 2008-12-24 |
| IL157713A0 (en) | 2004-03-28 |
| EP1373206A1 (en) | 2004-01-02 |
| ATE418542T1 (de) | 2009-01-15 |
| HK1057211A1 (en) | 2004-03-19 |
| US6689783B2 (en) | 2004-02-10 |
| MXPA03008801A (es) | 2004-02-18 |
| CA2442210A1 (en) | 2002-10-10 |
| MY134019A (en) | 2007-11-30 |
| CN1500078A (zh) | 2004-05-26 |
| JP4303969B2 (ja) | 2009-07-29 |
| KR20030083015A (ko) | 2003-10-23 |
| DE60230491D1 (de) | 2009-02-05 |
| ES2318009T3 (es) | 2009-05-01 |
| CA2442210C (en) | 2009-09-08 |
| CN1253435C (zh) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057786A2 (es) | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos | |
| AR033622A1 (es) | Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| PE20030007A1 (es) | Inhibidores de aldosa reductasa del grupo de las piridazinonas | |
| RU2009148796A (ru) | Производные пиперидина/пиперазина | |
| AR045587A1 (es) | Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| PE20090733A1 (es) | Derivados de pirazina como bloqueadores de los canales de sodio epitelial | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20141681A1 (es) | Inhibidores de btk | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| PE20040458A1 (es) | Piridinas sustituidas con actividad anti-angiogenica | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| AR035612A1 (es) | 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa | |
| AR047008A1 (es) | Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos. | |
| PE20010912A1 (es) | Derivados arilamina y su aplicacion como agentes antitelomerasa | |
| AR086676A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa | |
| AR036366A1 (es) | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |